I have a question regarding the sale of the diagnostics. When talking $.50 or plus per share for a sale, it's hard for me to rationalize a company with a $60 million market cap selling off assets for $.5 billion plus. Do you believe we are that vastly undervalued? Or is it that the liability for the costs of developing the therapeutics is so great that it is absorbing all of the earning potential of the diagnostics? If the latter is the case, what then can be expected to happen to the share price of the remaining therapeutic division once the diagnostic is separated? Long term I can see the value. Short term, I don't see how the market can be so far off in it's current valuation compared to what is being speculated we might fetch for the diagnostic division alone. Am I overlooking something or not understanding the process correctly?